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Available online 20 September 2014Abstract Lrig1 is an intestinal stem cell marker important for epithelial homeostasis. However, the position of the Lrig1+
population in the intestinal crypt has been debated, largely due to discrepant staining patterns using two Lrig1 antibodies. Here,
we set out to decipher the differences between these Lrig1 antibodies to clarify their use for Lrig1-related studies. We confirmed
that the commercially available Lrig1-R&D antibody stained the bottom third of the colonic crypt, whereas an independently
generated Lrig1-VU antibody recognized a subset of anti-Lrig1-R&D+ cells. Biochemically, we found that anti-Lrig1-VU recognized a
non-glycosylated form of Lrig1; in contrast, anti-Lrig1-R&D recognized both glycosylated and non-glycosylated forms of Lrig1. In
addition, we generated a reporter mouse (Lrig1-Apple) as an independent readout of Lrig1 transcriptional activity. Flow cytometry
of isolated colonic epithelial cells from Lrig1-Apple mice demonstrated anti-Lrig1-R&D recognized mostly RFP-hi cells, while
anti-Lrig1-VU recognized cells that were largely RFP-mid. Of note, by qRT-PCR, Lgr5 was expressed in the RFP-hi population, but
not in the RFP-mid population. We conclude that anti-Lrig1-R&D appears to recognize all Lrig1+ cells, while anti-Lrig1-VU
recognizes a subpopulation of Lrig1+ cells.
© 2014 Elsevier B.V. All rights reserved.Abbreviations: Lrig1, leucine-rich and immunoglobulin-like domains
protein 1; RFP, red fluorescent protein; FACS, fluorescence-activated
cell sorting; PCR, polymerase chain reaction; qRT-PCR, quantitative
real-time PCR.
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Identification of adult intestinal stem cell markers has
accelerated in recent years, following the discovery of the
first bona fide marker, Lgr5, by Barker et al., 2007 (Barker
et al., 2007). Powell et al. identified leucine-rich repeats
and immunoglobulin-like domains protein 1 (Lrig1) as an
intestinal stem cell marker in 2012 (Powell et al., 2012). At
the same time, Wong et al. demonstrated that Lrig1 was
important for intestinal homeostasis (Wong et al., 2012).
423Using a new Lrig1 reporter mouse to assess antibodies in the intestineWhile both groups demonstrated that Lrig1 marks cells in
the intestinal epithelial stem cell zone, discrepant obser-
vations of Lrig1 protein distribution in the intestinal crypt
were observed.
Wong and colleagues, focusing on the small intestine,
demonstrated that Lrig1 transcript and protein are expressed
in the progenitor cell zone of the crypt base using in situ
hybridization and immunofluorescent analysis. Using flow
cytometry, they showed that 30% of intestinal epithelial cells
express Lrig1 and these Lrig1+ cells express intestinal stem cell
marker transcripts (Wong et al., 2012). Our group—focused on
the colon—demonstrated that Lrig1 marks a bona fide intestinal
stem cell population that gives rise to all differentiated
intestinal epithelial cell types using lineage tracing studies.
Additionally, we showed that Lrig1 protein is expressed in select
cells in the colonic crypt base, rather than in a broad pattern.
Flow cytometry demonstrated that only 4.8% of colonic
epithelial cells express Lrig1; RNA-Seq analysis of this Lrig1+
flow-sorted population also revealed enrichment of intestinal
stem cell marker transcripts (Powell et al., 2012). The
relationship between different stem cell populations and
between stem cells and committed progenitors, as well as
studies of stem cell behavior, are marker-based. Therefore, it is
essential to clarify the Lrig1 expression discrepancy to facilitate
Lrig1-related studies.
These two independent studies utilized different anti-Lrig1
antibodies to assess Lrig1 protein expression. Wong et al. used
a commercial goat polyclonal anti-Lrig1 antibody from R&D
Systems™, raised against nearly the entire ectodomain of
mouse Lrig1 (#AF3688; hereafter anti-Lrig1-R&D) (Wong et al.,
2012), while in collaboration with Covance (Denver, PA),
Powell et al. generated a rabbit polyclonal peptide antibody
to a sequence (KILSVDGSQLKSY) in the ectodomain of mouse
Lrig1 (hereafter anti-Lrig1-VU) (Powell et al., 2012). Using a
new Lrig1 reporter mouse (Lrig1-Apple), we set out to further
characterize these antibodies to clarify their use for future
Lrig1-related studies. We show that anti-Lrig1-R&D appears to
recognize all Lrig1+ cells, while anti-Lrig1-VU recognizes a




The Lrig1-mAppleC1 construct was made by BAC recom-
bineering using the 129 Lrig1 BAC clone from the Sanger
Institute (bMQ291-E18). The Apple red fluorescent protein
variant excites at 568 nm and emits at 592 nm. The 5′ and 3′
oligonucleotide probes were generated by PCR; the primers
used for their generation are listed in Supplemental Table 1.
The Transgenic Mouse/ES Cell Shared Resource at Vanderbilt
University performed ES cell electroporation and blastocyst
injections. ES cell clones were screened by Southern blotting to
identify Lrig1-mAppleC1 integration. Chimeras were generated
and individuals with germline transmission were identified by
PCR genotyping of tail DNA (oligonucleotide primers listed in
Supplemental Table 1). Germline-transmitted Lrig1-mAppleC1
chimeras were intercrossed with FlpE mice (B6.SJL strain)
to eliminate the FRT-flanked PGK-neo cassette. Genotyping
PCR identified wildtype and Lrig1-Apple/+mice. Loss of thePGK-neo cassette was detected by PCR (oligonucleotide
primers listed in Supplemental Table 1). All animal
protocols were approved and performed in accordance
with the Vanderbilt University Medical Center Animal Care
and Use Program. Mice were fed standard rodent chow and
water ad libitum and housed under controlled light cycle
conditions.Cloning of Lrig1-EGFP and transfection
Full-length mouse Lrig1 cDNA (#MG50511-M, Sina Biological
Inc.) was cloned into the pEGFP-N1 plasmid (#6085-1,
Clonetech), resulting in the Lrig1-EGFP C-terminal fusion
protein. Lrig1-pEGFP-N1 (Lrig1-EGFP) and pEGFP-N1 (EGFP)
were transiently transfected into human HEK293T cells using
Metafectene (Biontex, Germany) according to the manu-
facturer's instructions.Isolation of colonic epithelium for western blotting,
cell lysis, and immunoprecipitation
Intestinal tissue was freshly dissected and crypts were isolated
as previously described (Powell et al., 2012; Whitehead et al.,
1987). Isolated crypt epithelium was lysed as previously
described (Powell et al., 2012). Protein concentrations were
determined using a microBCA assay kit (Pierce, Rockford, IL).
Thirty milligrams of lysates were resolved on a 7.5% SDS-PAGE
gel andwestern blotting was performed according to a standard
western blotting protocol. Autoradiography visualization was
performedwith ECL reagents (Perkin Elmer,Waltham,MA). The
following primary antibodies were used for western blotting:
anti-Lrig1-R&D 1:300 (#AF3688, R&D Systems, Minneapolis,
MN); anti-Lrig1-VU 1:300 (made in collaboration with Covance,
Denver PA (Powell et al., 2012)); anti-green fluorescent protein
(GFP) 1:1000 (#A11122, Invitrogen, Grand Island, NY); and
anti-α-tubulin 1:10,000 (#CP06, Calbiochem, San Diego, CA).
Species-specific HRP-conjugated secondary antibodies were
obtained from Jackson ImmunoResearch (West Grove, PA).
Transfected HEK293T cells were lysed with RIPA buffer (50 mM
Tris pH 7.2; 150 mM NaCl; 1% NP-40; 0.5% deoxycholic acid;
0.1% SDS) containing protease inhibitors (#P2714, Sigma, St.
Louis, MO). Lysates were centrifuged to remove the insoluble
pelleted fraction and the supernatant was used for immuno-
precipitation. Five hundred micrograms of cell lysates
were immunoprecipitated with anti-Lrig1-R&D, anti-Lrig1-VU,
or anti-GFP, and recovered using Dynabeads® Protein A
(#10001D, Invitrogen) or Dynabeads® Protein G (#10009D,
Invitrogen). Immunoprecipitates were resolved with SDS-PAGE
and western blotting as above.Peptide blocking
Wildtype mouse colonic crypt lysates were resolved by
SDS-PAGE. Twenty-fold molar excess of anti-Lrig1-VU blocking
peptide was added to anti-Lrig1-VU and anti-Lrig1-R&D and
incubated at 4°C for 4 h. The antibody-blocking peptide
solutions were diluted in 5% BSA-TBST as above and western
blotting was performed.
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Colonic crypt lysates were isolated and prepared as above. For
PNGaseF (#P0704S, New England Biolabs, Ipswich, MA) treat-
ment, colonic crypt protein lysates were treated according to
the manufacturer's instructions. Glycoprotein Denaturing Buff-
er was added to lysates to 1X final concentration and the
reaction denatured at 100°C for 10 min. G7 Reaction Buffer
and 10% NP-40 were added to the reaction to 1X and 1% final
concentrations, respectively. Fifty microliters of PNGaseF
were added to make up a total final reaction volume of 1 mL
and the reaction was incubated at 37°C for 1 h.In situ hybridization
Unfixed fresh mouse tissues were embedded in Tissue-Tek®
optimal cutting temperature (OCT) compound in a cold
ethanol-dry ice bath and stored at −80°C. Cryosections were
cut at 15 μm thickness. ISH was performed as previously
described (Li et al., 2004). The Lrig1 partial cDNA used for
probe synthesis was obtained by RT-PCR with total RNA from
isolated adult mouse colonic crypts. Primers used for RT-PCR
are provided in Supplemental Table 1. The synthesis of
digoxigenin (DIG)-labeled probes was performed according to
the manufacturer's protocols (Roche).Colonic crypt isolation and staining
Colonic epithelial crypts from wildtype and uninduced
Lrig1-CreERT2/+mice were isolated and stained as previ-
ously described (Tan et al., 2013). The following primary
antibodies were used for staining: anti-Lrig1-R&D 1:100
(#AF3688, R&D Systems, Minneapolis, MN) and anti-Lrig1-VU
1:100. Anti-phalloidin was a generous gift from Jim
Goldenring, M.D., Ph.D. Crypts were counterstained with
the nuclear marker DAPI.Tissue preparation and staining
Tissue preparation and staining were performed as previ-
ously described (Powell et al., 2011). Freshly dissected
intestinal tissues were fixed in 4% paraformaldehyde (PFA)
for 1 h at room temperature, washed and submerged in 30%
sucrose overnight at 4°C. The next day, fixed tissue was
embedded for cryosectioning in Tissue-Tek® OCT compound
and sectioned (5 μM sections) for staining. Immunostaining
on frozen cryosections was performed as previously de-
scribed (Davies et al., 2009). Direct fluorescence was used to
visualize RFP in Lrig1-Apple/+ tissue sections in the Cy3
channel. The following primary antibodies were used for
immunofluorescence: anti-Lrig1-R&D 1:100 (#AF3688, R&D
Systems, Minneapolis, MN); anti-Lrig1-VU 1:200 (generation
described in (Powell et al., 2012)); anti-Muc2 conjugated to
Cy5 1.5:100 (#sc-15334, Santa Cruz, Dallas, TX); and
anti-CD117 1:250 (c-Kit; #CBL1360, Millipore, Billerica,
MA). All sections were counterstained with DAPI. Slides
were visualized with an Olympus FV-1000 and Zeiss Imager
M2.FACS
Tissue for FACS was prepared as previously described (Powell
et al., 2012). Briefly, freshly dissected mouse intestine was
prepared and isolated crypts from Lrig1-Apple/+mice were
collected by slow centrifugation (400 rpm, 5 min). Crypts were
resuspended in 3% pancreatin solution for 90 min (Whitehead et
al., 1987), pipetted to single cells, and then resuspended in
Hams F12 medium with 1% FCS. DAPI (1:10,000; Sigma, St.
Louis, MO) was used as a viability marker. RFP-hi, RFP-mid, and
RFP-neg populations were isolated with a Becton Dickinson
FACSAria II using a 100 μm nozzle and placed on ice. Each cell
fraction was subsequently stained with either anti-Lrig1-VU
conjugated to Alexa-647 fluorophore (1:250) or anti-Lrig1-R&D
conjugated to Alexa-488 fluorophore (1:250; #FAB3688G, R&D
Systems) for 30 min on ice. Cells were then washed and
subsequently analyzed on a Becton Dickinson FACSAria II, using
DAPI (1:10,000) as a viability marker. Cell doublets were
eliminated on the basis of pulse width.
qRT-PCR analysis
Total RNA was isolated from FACS-isolated colonic epithelial
cells using a RNeasy Micro Kit (#14004, Qiagen, Germantown,
MD) and cDNA was made by reverse transcription using
SuperScript II (Invitrogen, Grand Island, NY). Triplicate qPCR
was done using the StepOnePlus Real-Time PCR system
(Applied Biosystems, Grand Island, NY). qPCR reaction compo-
nents were as follows: 0.1 μM primers, 4 mM MgCl2, and
EXPRESS SYBR GreenER Supermix with premixed ROX (A10315,
Invitrogen, Grand Island, NY) in a 20 μL reaction. The reaction
conditions were as follows: 50°C for 2 min, 95°C for 2 min;
95°C for 15 s, 58°C for 45 s (45 cycles), followed by a
melting curve. Data were analyzed using the ΔΔCT method.
The primer sequences for genes assayed are shown in
Supplemental Table 1.
Identification of Lrig1 glycosylation sites
We utilized the Glycoprotein database (GPDB) to identify
predicted and confirmed Lrig1 N-glycosylation sites, found
at http://jcggdb.jp/rcmg/gpdb/index (Kaji et al., 2012).
This group confirmed N-glycosylation sites using liquid
chromatography–mass spectrometry (LC-MS) from mouse
tissues (Kaji et al., 2003; Kaji et al., 2006). One confirmed
Lrig1 N-glycosylation site was identified from murine brain
tissue at N76; predicted Lrig1 N-glycosylation sites included:
N152, N248, N294, N320, N385, and N686.
Results
Anti-Lrig1-VU recognizes a subset of anti-Lrig1-R&D+
cells
We first compared the reactivity of each anti-Lrig1 antibody
on isolated mouse colonic crypts by immunofluorescence.
Consistent with previously published results, anti-Lrig1-R&D
recognized nearly every epithelial cell in the bottom third of
the crypt base (Fig. 1A, A′) (Wong et al., 2012). In contrast,
anti-Lrig1-VU stained a subset of cells in the crypt base
Figure 1 Anti-Lrig1-VU recognizes a subset of anti-Lrig1-R&D+ cells. A–B′. Immunofluorescent analysis of isolated mouse
colonic crypts with anti-Lrig1-R&D (A; A′, white) or anti-Lrig1-VU (B; B′, white) counterstained with DAPI (A′, B′, blue). C–C‴.
Single and co-immunofluorescence of isolated mouse colonic crypts with anti-Lrig1-R&D (C; C″, C‴, green) and anti-Lrig1-VU (C′;
C″, C‴, red). D. Visualization of red fluorescent protein (RFP, red) in colonic tissue sections from Lrig1-Apple/+mice, counterstained with
phalloidin (white) to mark epithelial cells. E. Lrig1 in situ hybridization in mouse colonic tissue sections. All scale bars represent 25 μM.
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Co-immunofluorescence using both anti-Lrig1 antibodies re-
vealed that anti-Lrig1-VU immunoreactivity (Figure 1C′; 1C″,
1C‴, red) was restricted to a subset of anti-Lrig1-R&D+ cells
(Fig. 1C; 1C″, 1C‴, green). Lrig1 is a type I transmembrane
protein and is expected to be located on the plasmamembrane
(Nilsson et al., 2001). We observed that the immunoreactive
patterns of both antibodies were largely restricted to the
basolateral membrane of epithelial cells within the crypt base,
although cytoplasmic staining was previously observed with
anti-Lrig1-VU in mouse colonic tissue sections (Powell et al.,
2012); we observed no nuclear immunoreactivity with either
antibody. To facilitate our analysis, we generated a Lrig1
reporter mouse, Lrig1-Apple, which produces Apple fluores-
cent protein, a red fluorescent protein (RFP) variant, undercontrol of the Lrig1 promoter (Supplemental Fig. 1). Hereaf-
ter, we refer to this reporter mouse as Lrig1-Apple and Apple
fluorescence as RFP. While RFP expression may not directly
correlate with Lrig1 transcript expression, it serves as a
surrogatemarker for Lrig1 promoter activity.We detected RFP
expression in the base of every crypt along the length of both
the small and large intestines (Supplemental Fig. 2; Fig. 1D)
and observed consistent immunoreactive patterns with both
Lrig1 antibodies in Lrig1-Apple/+ small intestinal and colon-
ic tissue sections (Supplemental Fig. 3). In particular, RFP was
expressed in the colonic crypt base of Lrig1-Apple/+mice in a
pattern that closely resembled the anti-Lrig1-R&D immuno-
reactive zone (Fig. 1D), consistent with Lrig1 in situ
hybridization (Fig. 1E). These observations suggest that
the anti-Lrig1-R&D immunoreactive pattern more faithfully
426 E.J. Poulin et al.mirrors the Lrig1 transcriptional readout than anti-Lrig1-VU,
which recognizes a subset of cells with Lrig1 promoter
activity and anti-Lrig1-R&D immunoreactivity.Lrig1-R&D and Lrig1-VU antibodies react specifically
with Lrig1 protein
To determine the basis for the discrepancy in tissue staining
patterns, we took a biochemical approach to directly compare
anti-Lrig1-R&D and anti-Lrig1-VU. We previously validated
anti-Lrig1-VU on Lrig1−/− colonic tissue sections and on
intestinal epithelial cell lysates from Lrig1-CreERT2/CreERT2
mice, which lack Lrig1 protein (Powell et al., 2012). To further
test the specificity of the two anti-Lrig1 antibodies, we
performed western blot analysis using colonic epithelial cell
lysates from Lrig1-Apple/Apple (Lrig1-Ap/Ap) mice. The
Lrig1-Apple allele was designed such that themAppleC1 coding
sequence replaces that of endogenous Lrig1 at the translational
initiation site; Lrig1-Apple/Apple mice are therefore null for
Lrig1 (Supplemental Fig. 1; Fig. 2A). Neither Lrig1 antibody
detected Lrig1 protein in Lrig1-Apple/Apple tissue lysatesFigure 2 Anti-Lrig1-R&D and anti-Lrig1-VU react specifically wit
(Lrig1-Ap/Ap) or wildtype (WT) mouse colonic epithelial cell lysates
as a loading control. B. Western blot analysis of wildtype mouse co
with or without an anti-Lrig1-VU blocking peptide. C. GFP (lanes 3–4
HEK293T cell lysates, followed by western blot analysis for Lrig1
predicted to be 146 kDa. Arrow indicates the Lrig1-specific band. D
after treatment with the N-glycosidase, PNGaseF, using anti-Lrig
demonstrate effective PNGaseF activity. CTL, control, untreated sacompared to lysates from wildtype mice. Addition of an
anti-Lrig1-VU blocking peptide to anti-Lrig1-VU and anti-Lrig1-
R&D partially blocked Lrig1 detection by western blot analysis
(Fig. 2B), validating the specificity of anti-Lrig1-VU and
confirming the anti-Lrig1-VU epitope lies within that of
anti-Lrig1-R&D.
To further examine specificity, we generated a construct
encoding EGFP-tagged mouse Lrig1 (Lrig1-EGFP), transiently
expressed it in human HEK293T cells, and performed recipro-
cal immunoprecipitation and western blot analysis (Fig. 2C).
Both Lrig1 antibodies detected Lrig1-EGFP following GFP
immunoprecipitation, indicating specificity for Lrig1 protein.
In addition, anti-Lrig1-VU detected Lrig1-EGFP following
immunoprecipitation with anti-Lrig1-R&D. We observed nu-
merous non-specific bands that may reflect non-specific
binding of anti-Lrig1-VU and GFP cleavage or degradation
products. These results suggest that anti-Lrig1-R&D and
anti-Lrig1-VU recognize the same protein in vitro.
The main difference between these two antibodies is their
respective epitopes. Anti-Lrig1-R&D was raised against nearly
the entire Lrig1 ectodomain (Ala37-Thr794). In contrast,
anti-Lrig1-VU was raised against a short peptide sequence inh Lrig1 protein. A. Western blot analysis of Lrig1-Apple/Apple
for Lrig1 using anti-Lrig1-R&D or anti-Lrig1-VU. α-tubulin serves
lonic crypt lysate probed with anti-Lrig1-R&D and anti-Lrig1-VU
) or anti-Lrig1-R&D (lanes 5–6) immunoprecipitation from human
using anti-Lrig1-R&D, anti-Lrig1-VU, or anti-GFP. Lrig1-EGFP is
. Western blot analysis of wildtype mouse colonic crypt lysate
1-R&D and anti-Lrig1-VU. Egfr serves as a positive control to
mple.
Figure 3 FACS sorting reveals differences between anti-Lrig1-R&D+ and anti-Lrig1-VU+ cell populations. A. Fluorescence-activated
cell sorting (FACS) analysis of isolated Lrig1-Apple/+ colonic epithelial cells into RFP-hi, -mid, and -neg populations. B, C. Relative
Lrig1 (B) and Lgr5 (C) expression from FACS-isolated RFP-hi, -mid, and -neg Lrig1-Apple/+ colonic epithelial cells (expression levels
from whole colon crypts are shown for Lgr5 as a control). RQ, relative quantity. D. FACS analysis of RFP-hi, -mid, and -neg
Lrig1-Apple/+ colonic epithelial cells co-sorted with anti-Lrig1-R&D (conjugated to Alexa-488) or anti-Lrig1-VU (conjugated to
Alexa-647). Percentages indicate the number of cells above the quadrant gate drawn at approximately 200 cells.
427Using a new Lrig1 reporter mouse to assess antibodies in the intestinethe Lrig1 ectodomain (KILSVDGSQLKSY), corresponding to
Lys128-Tyr140. The anti-Lrig1-R&D antigen is much larger,
which may allow greater epitope accessibility and be more
permissive of post-translational modifications, such as glyco-
sylation. In 2012, Kaji et al. published a global LC-MS
glycoprotein analysis using various mouse tissue lysates (Kaji
et al., 2012). Using the GlycoProtein Database (GlycoProtDB)
constructed by this group, we found seven predicted
N-glycosylation sites within the Lrig1 protein (Kaji et al.,
2012). Without taking the three-dimensional folded structure
into account, there is one predicted N-glycosylation site near
the linear anti-Lrig1-VU antigenic peptide sequence: Asp152(GlycoProtDB). To test this, we treated wildtype mouse
colonic crypt lysates with the N-glycosidase, PNGaseF, and
observed that the form of Lrig1 recognized by anti-Lrig1-R&D
underwent a shift to a faster migrating form, consistent with
deglycosylation (Fig. 2D). In addition, we observed increased
intensity of the band recognized by anti-Lrig1-VU, suggesting
that deglycosylation generated a larger pool of the Lrig1 form
recognized by anti-Lrig1-VU (Fig. 2D). It should be noted that
this increased band intensity was variable. These data suggest
that both anti-Lrig1 antibodies are specific for themouse Lrig1
protein, but Lrig1 glycosylation may affect the ability of
anti-Lrig1-VU to recognize Lrig1.
428 E.J. Poulin et al.FACS sorting reveals differences between
anti-Lrig1-R&D+ and anti-Lrig1-VU+ cell populations
To characterize the cell populations recognized by these
two Lrig1 antibodies, we performed fluorescence-activated
cell sorting (FACS) analysis on colonic epithelial cells from
Lrig1-Apple/+mice using the total colon as input. Cells were
isolated on the basis of RFP expression into RFP-hi, -mid, and
-neg cells (Fig. 3A; Supplemental Fig. 4). We performed
qRT-PCR to validate FACS-isolated cells expressed proportional
Lrig1 transcript levels (Fig. 3B). RFP-neg cells did not express
Lrig1, supporting the use of RFP as a Lrig1 readout in this in vivo
system. To determine whether there were differences be-
tween the RFP-hi and -mid populations other than Lrig1, we
performed qRT-PCR for additional intestinal transcripts of
interest. Therewere no appreciable difference in expression of
Villin1, carbonic anhydrase 1 (Car1), and Mucin 2 (Muc2)
(Supplemental Fig. 5A, B, C). Muc2 protein expression was
distributed evenly throughout colonic crypts (Supplemental
Fig. 5D). c-Kit transcript expression was not detectable by
qRT-PCR (Supplemental Fig. 5E), which potentially reflects the
small number of RFP+ cells that express c-Kit protein
(Supplemental Fig. 5F). Of note, we observed the RFP-hi pop-
ulation expressed Lgr5, while RFP-mid and -neg populations did
not (Fig. 3C). This supports our previous data where we showed
that there is a population of Lrig1-expressing cells distinct from
the Lgr5 stem cell population (Powell et al., 2012).
To determine which RFP subpopulation was preferentially
recognized by each antibody, we individually stained live
RFP-hi, -mid, and -neg cells with each anti-Lrig1 antibody, and
immediately re-analyzed them by flow cytometry. Anti-Lrig1-
R&D (conjugated to Alexa-488) recognized 98% of RFP-hi cells,
while anti-Lrig1-VU (conjugated to Alexa-647) recognized only
12%. Anti-Lrig1-VU recognized mostly RFP-mid cells (44%) and
displayed three apparent populations of reactivity (Fig. 3D),
similar to what was observed whenwe applied this antibody to
total colonic epithelium (Powell et al., 2012). Interestingly,
anti-Lrig1-R&D recognized 26% of RFP-neg cells, which may
complicate its use for cell sorting. While both anti-Lrig1
antibodies are specific to Lrig1 protein by biochemical
analysis (Fig. 2A), these results indicate biological differ-
ences in the Lrig1-expressing cell populations recognized by
each antibody.
Discussion
Lrig1 marks an intestinal stem cell population, but due to
reagent differences, the position of Lrig1 in the intestinal
epithelium is unclear. We set out to characterize the
differences between two Lrig1 antibodies: one available
commercially, anti-Lrig1-R&D, and one generated indepen-
dently, anti-Lrig1-VU. In addition, we generated a new tool
to study Lrig1: a Lrig1 reporter mouse, Lrig1-Apple that
reflects Lrig1 transcriptional activity. From our studies
here, we conclude: (1) both Lrig1 antibodies are specific to
Lrig1; (2) anti-Lrig1-R&D immunoreactivity closely mirrors
Lrig1 transcriptional activity, as determined by high RFP
reporter expression and Lrig1 in situ hybridization; and (3)
anti-Lrig1-VU recognizes a subset of Lrig1+ that express a
non-glycosylated form of Lrig1. While it is clear that
anti-Lrig1-VU marks a stem cell population (characterized inPowell et al., 2012), this population appears to be a
subpopulation of the total Lrig1+ population. Therefore, we
conclude that anti-Lrig1-R&D recognizes all Lrig1+ cells and
anti-Lrig1-VU recognizes a discrete subpopulation of Lrig1+
cells that have a gene expression profile consistent with that
of a stem cell and different from the Lgr5 stem cell (Powell et
al., 2012).
The most obvious explanation for the observed discrepancy
between these two antibodies is their respective antigenic
differences: anti-Lrig1-R&D is raised against nearly the entire
Lrig1 ectodomain (Ala37-Thr794), while anti-Lrig1-VU is raised
against twelve amino acids (Lys128-Tyr140) in the ecto-
domain. When an anti-Lrig1-VU-specific blocking peptide
was added, anti-Lrig1-R&D immunoreactivity was partially
blocked (Fig. 2B), suggesting that while the anti-Lrig1-VU
epitope lies within that of anti-Lrig1-R&D, anti-Lrig1-R&D
recognizes additional regions within the Lrig1 ectodomain.
While there is little structural information on Lrig1, the
anti-Lrig1-VU peptide lies within the leucine-rich repeat
domains of the ectodomain, which alone are not required
for Egfr association (Gur et al., 2004).
As the anti-Lrig1-VU epitope lies within that of
anti-Lrig1-R&D, it follows that anti-Lrig1-VU recognizes a
subset of anti-Lrig1-R&D+ cells. Interestingly, we have
demonstrated that this subset is likely marked by a form of
Lrig1 that is not glycosylated. As anti-Lrig1-VU recognizes
the RFP-mid population, we expect that this population
would express mostly non-glycosylated Lrig1, while the
RFP-hi population would express mostly glycosylated Lrig1.
Glycosylation is involved in multiple cell functions, includ-
ing protein–protein interactions, cell–cell adhesion, pro-
tein trafficking, cell surface receptor activation, and
endocytosis (Ohtsubo and Marth, 2006). Glycosylation
marks are dynamic and often change as the differentiation
status of a cell changes, as in the immune system (Daniels
et al., 2002), and abnormal glycosylation states are often
associated with cancer (Hakomori, 2002). It will be
important to determine whether the differential glycosyl-
ation status of Lrig1 between the total anti-Lrig1-R&D+
population and the anti-Lrig1-R&D+/anti-Lrig1-VU+ sub-
population has consequences relating to Lrig1 function
and the behavior of that stem cell population.
To begin to investigate how the total Lrig1+ population
differs from the anti-Lrig1-VU subset, we compared expres-
sion of various intestinal genes between RFP-hi, -mid, and
-neg cell populations from Lrig1-Apple/+colonic epithelial
cells. Of interest, we found that Lgr5 was expressed at the
highest level in RFP-hi cells, which are mostly recognized by
anti-Lrig1-R&D. In contrast, there was no Lgr5 expression in
RFP-mid (largely recognized by anti-Lrig1-VU) or RFP-neg
cells. Since cells marked by the Lgr5-EGFP reporter are highly
proliferative, this observation indicates that the proliferative
status of RFP-hi and RFP-mid may differ. We previously
showed that 25% of anti-Lrig1-VU+ cells were also Ki67+,
while Lgr5-EGFP+ cells are more highly proliferative (Powell et
al., 2012). We also demonstrated that anti-Lrig1-VU+ cells are
distinct from Lgr5-EGFP+ cells (Powell et al., 2012). Here, we
demonstrate that most Lrig1+ cells do express Lgr5, but there
is a distinct subset (RFP-mid) that does not, and anti-Lrig1-VU
mostly recognizes this subset.
Technically, these two antibodies have their limitations.
Both are better suited for immunofluorescent analysis in
429Using a new Lrig1 reporter mouse to assess antibodies in the intestinefrozen tissue sections than in formalin-fixed paraffin-
embedded tissues. In addition, anti-Lrig1-VU did not work
for immunoprecipitation under our experimental conditions.
FACS analysis is feasible using both antibodies, but the gating
strategy used to separate Lrig1+ cells from background with
the Lrig1-R&D antibody is not ideal. Finally, the two anti-
bodies are not conducive to biochemical experiments when
used simultaneously. We were unable to perform FACS
analysis by sequential co-staining with both antibodies,
suggesting that they may compete for Lrig1 binding in vitro.
It should be noted that we observe non-specific staining in
the upper crypt with anti-Lrig1-VU. This effect is enhanced
upon simultaneous staining with anti-Lrig1-R&D, which also
displays similar non-specific staining under these conditions
(Fig. 1C-C‴).
This study describes a useful new tool for the study of
Lrig1: the Lrig1-Apple reporter mouse. Other intestinal
stem cell reporter mice, such as Lgr5 (Barker et al., 2007;
Breault et al., 2008) and mTert (Breault et al., 2008)
express green fluorescent protein (GFP). The Lrig1-Apple
RFP reporter is therefore perfectly compatible with such
GFP reporters to compare multiple stem cell populations in
the same tissue. As Lrig1 is broadly expressed in many
tissues (Nilsson et al., 2003), the Lrig1-Applemouse will be
a useful tool to examine the role of Lrig1 outside the
intestine. It is important to note that in this model, RFP
serves as a readout of Lrig1 transcriptional activity only
and may not accurately reflect the true regulated Lrig1
transcriptional unit or protein status in real time.
Although profiling of the entire Lrig1+ population is still
lacking (but feasible using anti-Lrig1-R&D), RNA-Seq anal-
ysis demonstrated that the anti-Lrig1-VU+ cell profile is
characteristic of a stem cell population (Powell et al.,
2012). Immunofluorescent analysis using anti-Lrig1-VU
demonstrates that the position of this subpopulation in
the colonic crypt varies; it should be emphasized that the
anti-Lrig1-VU+ cell position is not restricted to the crypt
base columnar cell zone or the +4 position, but varies, most
often occupying positions 2–5 (quantified in Powell et al.,
2012).
In summary, we believe this study will be of interest to the
intestinal stem cell field. There has been a reluctance to accept
Lrig1 as an intestinal stem cell marker because of the
discrepancies between the two Lrig1 studies published in 2012
(Powell et al., 2012; Wong et al., 2012). Here, we hope to have
clarified differences between two Lrig1 antibodies and the
respective Lrig1+ populations they recognize. We suggest the
following usage for study of mouse Lrig1: to study all Lrig1+ and
Lrig1+ cells in the intestinal crypt, we recommend using
anti-Lrig1-R&D; when studying the Lgr5-/Lrig1+ stem cell
subpopulation, we recommend using anti-Lrig1-VU. In addition,
real time comparison of Lrig1+ cells with other stem cell
populations expressing GFP reporters is now possible with the
use of Lrig1-Apple reporter mice in conjunction with anti-Lrig1-
VU.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2014.09.002.
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